Savient Wins Generic Restraining Order For Oxandrin

Law360, New York (December 5, 2006, 12:00 AM EST) -- Keeping generic companies at bay, drug maker Savient Pharmaceuticals Inc. has won a temporary restraining order halting the sale of all generic forms of weight-gain drug Oxandrin in its patent infringement suit against Novartis AG unit Sandoz Pharmaceuticals and Upsher-Smith Laboratories Inc.

The temporary restraining order (TRO) was granted Monday after Savient filed the suit earlier that day in the U.S. District Court for the District of New Jersey, alleging that the generic drug makers were violating five of its patents covering methods of using Oxandrin....
To view the full article, register now.